艾伯维Abbvie Inc (ABBV) 2022年年度报告「NYSE」.pdf

1、2022 Annual Report on Form 10-K2023 Notice of Annual Meeting&Proxy StatementA decade of impactEndlesspossibilitiesAfter 10 Years:Our Impact on Patients,Science and our Community30+ProductsToday,AbbVie has a diverse portfolio of 30+on-market products and is focused on several key therapeutic areas:-I

2、mmunology-Oncology-Aesthetics-Neuroscience-Eye care50+Compounds in Late Stage Development13KParticipants in Week of PossibilitiesIn 2022,13,000 volunteers in more than 50 countries and territories participated in AbbVies annual Week of Possibilities.Donated$650M Since our inception,AbbVie and the Ab

3、bVie Foundation have donated almost$650 million to nonprofits around the world and built a culture that has come to define our company.40+Top Employer Rankings GloballyAbbVie appears on more than 40 Top Employer and Great Place to Work rankings globally.25Major product or indication approvals since

4、2013Printed on recycled paperStockholder InformationAbbVie Inc.Corporate Headquarters1 North Waukegan RoadNorth Chicago,IL Investor RelationsDept.ZZ05,AP34Corporate SecretaryDept.V364,AP34Stock ListingThe ticker for AbbVies common stock is ABBV.The principal market for the AbbVie common stock is the

5、 NYSE.AbbVie common stock is also listed on the Chicago Stock Exchange.Annual MeetingThe Annual Meeting will be held on Friday,May 5,2023,at 9 a.m.CT.Please see the proxy statement for information about how to attend the virtual Annual Meeting.Dividend Reinvestment PlanThe AbbVie Dividend Reinvestme

6、nt Plan offers registered stockholders an opportunity to purchase additional shares,commission-free,through automatic dividend reinvestment and/or optional cash investments.Interested persons may contact the transfer agent.Transfer AgentEQ Shareholder ServicesP.O.Box 64874St.Paul,MN 55164-877.881.59